THERION BIOLOGICS CORP


Jun 03, 06

NEW STORY
11:30 ET Therion Reports Results of Phase 2 PROSTVAC(R)-VF Trial at ASCO Annual Meeting and Formalizes Plan for an NCI-Sponsored Phase 3 Study

 
Jun 01, 06

08:30 ET Therion Biologics Announces Conclusion of PANVAC-VF Phase 3 Trial

 
Feb 10, 06

08:01 ET Therion Completes Phase III Enrollment for PANVAC-VF Pancreatic Cancer Trial; BLA Planned for 2006

 
Jul 07, 05

09:53 ET Therion Biologics Corporation Completes Enrollment in Phase II Clinical Trial of PROSTVAC(R)-VF in Androgen Independent Prostate Cancer

 
08:51 ET Therion Biologics Corporation Completes Enrollment in Phase II Clinical Trial of PROSTVAC(R)-VF in Androgen Independent Prostate Cancer

 
Jun 17, 05

08:59 ET Therion Biologics Corporation Secures $30 Million in Private Equity Financing

 
May 11, 05

09:15 ET Therion Announces Upcoming Oral and Poster Presentations at ASCO on Lead Programs in Prostate and Pancreatic Cancer

 
Jan 06, 05

09:20 ET Therion Biologics Establishes Clinical Advisory Board to Guide the Development of its Multiple Therapeutic Cancer Vaccine Programs

 
Dec 22, 04

08:02 ET Researchers Publish Supporting Safety and Anti-tumor Activity of Therion Biologics' CEA-TRICOM(TM) Therapeutic Vaccine in Journal of Clinical Oncology

 
Oct 29, 04

10:01 ET Therion Biologics to Present at Mass Opportunities Biotechnology Investment Conference

 
Jul 28, 04

08:10 ET Therion Biologics Named Among Top 15 Emerging Biotech Companies Of 2004

 
Jun 21, 04

08:33 ET Therion Biologics Corporation Initiates Phase III Clinical Trial With PANVAC(TM)-VF In Advanced Pancreatic Cancer

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2006 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.